We examined the relationship between serially measured, novel serum biomarkers and a measure of cognitive functioning in older adults. We assayed stored serum samples from two Fels Longitudinal Study visits in N = 100 adult participants (visit 1 ages 59.3 ± 8.5 years; 53% female), and Montreal Cognitive Assessment (MoCA) scores also assessed at the second visit. Assays included acylcarnitines, amino acids, and 2-hydroxybutyric acid (b-HBA). Cross-sectional correlations between acylcarnitines and amino acids and MoCA were identified. Serial change in short-chain acylcarnitines and visit 2 MoCA were also correlated. Participants with MoCA scores <26 were more likely to have an increase in short-chain acylcarnitines between visits 1 and 2 [adjusted odds ratio (OR) = 5.24; 95% confidence interval (CI) 1.07-25.9]. b-HBA was also correlated with acylcarnitines. Several cross-sectional and serial associations between novel serum biomarkers and cognitive functioning were identified. b-HBA may also be a cost-effective marker of dysregulation associated with cognitive decline.
Dementia is emerging as a major public health concern in the United States. While it is devastating for the person who has it and their loved ones, dementia care is costly to the health care and social services sectors and to the overall U.S. economy as a whole since productive workers and volunteers often leave their positions to care for family members. The prevalence of dementia shows no signs of abating since an additional 10 million baby boomers are expected to develop dementia over the next decade, placing further strain on health, and social services. Although relative proportions of causes of death due to other major diseases have decreased in the last several years, the proportion due to dementia has risen substantially such that dementia is now the sixth leading cause of death in the United States (1) .
This epidemiologic imperative is driving robust research in the basic and clinical neurosciences, social sciences, health care delivery, and assistive technologies. In turn, findings from these research activities should provide key information to specialty organizations, policy makers, and insurers who will play important roles in how dementia care is delivered in the United States.
Biomarkers have emerged as crucial components in the search for the cause of dementia, and are lynchpins in the work that will lead to pharmacotherapeutic breakthroughs. Since there is compelling evidence that biomarkers may precede symptomatic disease by decades, further elucidation about their characteristics may also pave the way for prevention. Example of biomarkers for Alzheimer's disease (AD), characterized by amyloid plaques and neurofibrillary tangles, include (a) cerebrospinal fluid (CSF) markers, namely CSF Aβ1-42, T-tau, and P-tau Thr181 and Thr231 proteins and (b) imaging markers, such as anatomical or volumetric magnetic resonance imaging showing hippocampal atrophy, molecular in vivo amyloid imaging agents, and markers of neurodegeneration, such as fluoro-2-deoxy-D-glucose (FDG) (2) .
Quantification of small molecule metabolites, or metabolomics, is now being explored as an approach to better understand how disruption of metabolic pathways in the brain can lead to neurocognitive impairment (3) (4) (5) (6) (7) (8) (9) (10) (11) . Evidence that spans both mouse and human models suggests that disrupted energy metabolism within the brain (12, 13) , at the blood-brain barrier (14) , and in other systems, eg, circulatory (15) and musculoskeletal (16) , are related to neurological deficits and dementia. While this line of work is still in its infancy, mitochondrial dysfunction is proposed as one of the dysregulated energetic pathways leading to the appearance of plaque deposition and neurofibrillary tangles in the brain (13, 17) . Further, although fat is not the primary source of fuel in the brain, the role of acylcarnitines in the functioning of the mitochondria in the brain and for other neuroprotective properties needs further examination (18) .
Outside the central nervous system, mitochondrial dysfunction via incomplete fatty acid oxidation may be represented by elevated concentrations of acylcarnitines, which are intermediates in the breakdown of long-chain fatty acids in the mitochondria. In dysregulated mitochondria, accumulated acylcarnitines are released into the circulation (19, 20) and may be related to neurocognitive decline. For example, 2-hydroxybutyric acid (b-HBA) is a ketone body produced in the liver via fatty acid catabolism in the mitochondria. Previous studies have linked liver mitochondrial dysfunction to cognitive impairment (21) , and Ciavardelli et al. (17) reported an association between low circulating acylcarnitine concentrations and low b-HBA acid concentrations in cognitively impaired elders. A prevailing theory is that in the presence of impaired mitochondrial function in the diseased brain, alternative fuel sources to glucose, including ketone bodies, are utilized for brain functioning (22) . This dysregulation that manifests as the symptom of cognitive impairment later in life may be the result of decades of gradual, perhaps unnoticed, declines in multiple systems.
Several reports have investigated the relationship between amino acid metabolism and cognitive function, although the findings are mixed and the data are not robust. In both mild cognitive impairment and Alzheimer's dementia, some amino acids increase, while others decrease as a result of their oxidation as neuronal energy sources when glucose catabolism becomes impaired. For example, the neuronal glutamate-glutamine cycle has been shown to be disrupted in AD and mild cognitive impairment (23) , and excess proline has been implicated in the prevention of glutamate uptake in the brain (24) . Other investigations have linked the modification of amino acids and nitroxidative stress in the brain (25) . Amino acids that have been reported to date to be associated with dementia are glutamine/glutamate, leucine, valine, tyrosine, lysine, and cysteine (26) .
At this time, metabolomics studies have not consistently demonstrated significant links to serum levels of amino acid, or to other biomarkers such as acylcarnitines and ketone bodies, and cognition. Thus, the purpose of this study was to determine the relationship between a number of novel biomarkers (acylcarnitines, 2-HBA, and amino acids) measured at two points in time and cognitive functioning in older adults utilizing the rich serial data from the Fels Longitudinal Study.
Methods

Data Source and Participants
A detailed description of the Fels Longitudinal Study has been previously published (27) . Briefly, the study began in 1929 for the purpose of examining growth, maturation, and body composition of individuals residing in southwest Ohio. In many cases, participants were enrolled as newborns, infants, or small children, and then followed throughout their life spans. Others were added during adolescence or adulthood, with a total sample of approximately 1200 active, serial participants. Although the study is closed to additional recruitment, data collection in a substantial number of participants is ongoing. Participants follow specific visit schedules depending on age and sex; for participants ≥18 years of age, visits occur every 2-5 years. Fels participants are overwhelmingly of European descent and typically live in southwest Ohio, roughly mirroring that region's distribution of socioeconomic status, although Fels participants are well-educated with ~80% having at least some college education. Participants are not targeted for study enrollment because of any particular health conditions, diseases, or body composition, and as such, the study can be considered to approximate normal population variation within the represented demographic.
Participants were selected for the present analysis if they had two visits (in this report referred to as visits 1 and 2) after the age of 50 with viable stored biosamples that were selected and assayed in 2016. Additionally, visit 2 included the administration of the Montreal Cognitive Assessment (MoCA). This resulted in a convenience sample of N = 100 participants for this analysis.
In addition to age and gender, grip strength, body mass index (BMI), and prevalence of sarcopenia [dual-energy absorptiometry (DXA) acquired appendicular lean mass/stature 2 ] were documented to characterize the prevalence of frailty among the study cohort. The number of chronic medical conditions was recorded to further characterize the study cohort, and physical and mental functioning was characterized using the MOS 36-item Short-Form Health Survey (SF-36) subscales (28) . There were no measures of depression collected at study visits, so the SF-36 mental functioning subscale was utilized as a proxy based on previous reports supporting its validity as a screen for depression (29) . These data were all collected and documented at visits 1 and 2.
For evaluating cognitive function, the MoCA was performed on all participants at the second visit 2 only. This was collected as part of ancillary funding at the time focused on the cognition of the study participants. The MoCA, a well-validated 30-item test of cognition, has been shown to identify cognitive deficits, with a score of less than 26 accurately identifying at least mild cognitive impairment in individuals who are on the younger spectrum of older adulthood and well-educated, as are the Fels participants in this analysis (30, 31) . A cut-off of 26 remains the standard of care for initial concern in the clinical setting. As such, the study cohort was divided into two groups: those with a MoCA score of 26 or above, consistent with a normal cognitive score (">26 MoCA group"), and those with a MoCA score of less than 26 ("<26 MoCA group.") The <26 MoCA group represents those with the potential for underlying cognitive impairment for a population from which this sample was drawn; however, more formal neurological testing would be needed to confirm underlying impairment. We dichotomized MoCA scores at 26 to examine biomarker associations purely from a clinical perspective, which if seen in practice, could result in a clinician's raised level of concern and closer follow-up.
All study procedures were approved by the Institutional Review Board at Wright State University and all participants provided informed consent prior to participation.
Molecular Profiling
All venous blood samples were obtained in an overnight fasting state. Whole blood was obtained via venipuncture and collected in anticoagulant-treated tubes. Plasma was then immediately separated via centrifuge, transferred to polypropylene tubes via pipette, appropriately labeled, and frozen at −80°C. Frozen samples were sent to the Duke Molecular Physiology Institute for analysis. Fortytwo acylcarnitines and 15 amino acids were analyzed using stable isotope dilution techniques. The measurements were made by flow injection tandem mass spectrometry using sample preparation methods as described previously (32, 33) . The data were acquired using a Waters triple quadrupole detector equipped with Acquity TM UPLC system and controlled by MassLynx 4.1 software platform (Waters, Milford, MA). The b-HBA was measured on a Beckman DxC600 clinical analyzer using regents from Wako Diagnostics (Mountain View, CA).
Statistical Analysis
Characteristics of study participants were calculated using appropriate univariate continuous or frequency statistics. All biomarker values were transformed by the natural log (with a constant of one added to the raw values to deal with values of zero) because of their skewed distribution. In consistent with previous methods to combine individual acylcarnitines into biologically meaningful groups, and to reduce the dimensionality of the 42 individual species (19, 20) , we created summary short, medium, and long-chain variables based on the sum of C2-C6 (short-chain), C8-C12 (medium-chain), and C14-C18 (longchain) acylcarnitines. Spearman correlations were calculated between acylcarnitines, amino acids, and 3-HB ketone (and their change from visits 1 to 2), and MoCA. Multivariate logistic regression models were used to determine associations between groups (>26 MoCA vs <26 MoCA) and visits 1 and 2 acylcarnitines, amino acids and b-HBA, and their change (visit 2 -visit 1). Covariates included in all models included sex, age, grip strength (a continuous measure of sarcopenia risk), SF-36 mental health functioning subscale (as a proxy for depression), and number of chronic conditions. Visit 1 covariate information was used when examining associations at visit 1 and their change from visits 1 to 2. Visit 2 covariate information was used when examining visit 2 associations. The amount of time between visits was included as a covariate when examining associations between changes in biomarkers between visits 1 and 2, and MoCA groups. All analyses were conducted using SAS version 9.4 (SAS, Cary, NC).
Results
Visits 1 and 2 Characteristics
The mean age at visit 1 was 59.3 ± 8.5 years and 53% of the participants were female. Almost 80% of the participants had some college education, which is very comparable to the larger Fels cohort (Table 1) . Other visit 1 characteristics included a BMI that on average was overweight, with a low prevalence of sarcopenia (23%). The mean number of chronic conditions was less than one and both SF-36 physical (83.2 ± 18.7) and mental (82.0 ± 13.6) functioning scores indicated good functioning. As a whole, this sample of Fels participants had characteristics that were representative of the larger group. This is a uniquely dedicated study population in that they are enrolled at birth, in many instances are multigenerational in their participation, and study visits are a normal aspect of their lives from birth.
At visit 2 (Table 2) , the visit at which MoCA was measured, there were 53 subjects who scored less than 26 on the MoCA (range of [18] [19] [20] [21] [22] [23] [24] [25] , and 47 subjects who scored 26 or higher (range of [26] [27] [28] [29] [30] . The mean time between visits 1 and 2 was 3.6 years (range 2.0-8.8 years). None of the participants reported a diagnosis of impaired cognitive function at either study visit. Participants in the <26 MoCA group at visit 2 were older with a higher proportion being male, although neither characteristics were statistically different from the >26 MoCA group. Being in the <26 MoCA group was associated with higher concentrations of short, medium, and long-chain acylcarnitines (all p < .05), and while mean b-HBA concentrations were disparate between MoCA groups (80.1 vs 39.0), there was considerable variability in the measure. Amino acid concentrations were not statistically different between groups, with the exception of ornithine (p = .02). Glycine and phenylalanine concentrations demonstrated a trend for differences between groups (both p ≤ .10). While not statistically significant, SF-36 physical functioning subscale scores in the <26 MoCA group (77.9 ± 20.2) were lower than the >26 MoCA group (85.1 ± 19.1), indicating a clinically relevant difference in physical functioning (34, 35) . Both groups' mean physical functioning scores at visit 2 were only approximately two points lower than they were at visit 1 (<26 MoCA group = 79.4 ± 20.8; >26 MoCA group = 87.3 ± 15.2), representing little change in self-reported functioning between visits. Note: AC's = Acylcarnitines; H.S. = High school. 
Correlations of Characteristics/Biomarkers with MoCA
Correlations between participant characteristics and biomarkers at visits 1 and 2 with MoCA scores can be seen in Table 3 . Being female and a higher SF-36 physical functioning score at visit 2 was positively correlated with MoCA. Whereas all other significant correlations with MoCA were inverse and were predominantly visit 2 measures, including age, number, or chronic conditions, SF-36 mental function score, and short, medium and long-chain acylcarnitine concentrations. At both visits 1 and 2 glutamine/glutamic acid and ornithine concentrations were negatively correlated with MoCA, and change in short-chain acylcarnitines between visits was also negatively correlated with MoCA.
Correlations of b-HBA with Acylcarnitines by MoCA Group
Following the work of Ciavardelli et al. (17), we examined the associations between circulating acylcarnitines and b-HBA, and if associations differed between MoCA groups (Table 4) . Positive b-HBA and acylcarnitine correlations were evident, and they were generally stronger in the <26 MoCA group compared to the >26 MoCA group. This held true at visits 1, 2, and their changes between visits, with the exception of change in medium-chain acylcarnitines. As an example, Figure 1 displays the plot of change in b-HBA with change in long-chain acylcarnitines in the MoCA groups. This adds further support to the cross-sectional findings of Ciavardelli et al. (17) , and we have extended this work in a longitudinal examination.
Likelihood of Low MoCA with Increased Biomarker Concentrations
We also examined the likelihood [adjusted odds ratios (OR) and 95% confidence intervals (95% CI)] of being in the <26 MoCA group with increased concentrations of circulating biomarkers that demonstrated bivariate associations with MoCA (Supplementary  Table 1 provides ORs and interquartile ranges). After adjusting for age, sex, grip strength, SF-36 mental functioning subscale score (a proxy for depression), number of chronic conditions, and time between study visits, we found an increase in short-chain acylcarnitine concentrations from visits 1 to 2 was associated with a higher odds of being in the <26 MoCA group (adjusted OR = 5.41; 95% CI 1.07-27.3). Lastly, we observed a trend toward higher concentrations of ornithine at visit 1 (adjusted OR = 1.02; 95% CI 1.00-1.05) and visit 2 (adjusted OR = 1.03; 95% CI 1.00-1.06) and odds of being in the <26 MoCA group.
Discussion
Key Findings
This study utilized serial data from the Fels Longitudinal Study to examine a wide range of novel circulating biomarkers and their association with cognition in functionally healthy older adults with no known diagnoses of dementia. The principle results have identified a significant association between high serum concentrations of short, medium, and long-chain acylcarnitines and lower scores on the MoCA cognitive testing at the same visit. In binomial analysis, a significantly increased odds of being in the <26 MoCA group was observed with increases in concentrations of short-chain acylcarnitines from visits 1 to 2. We also observed borderline associations between higher ornithine concentrations and the <26 MoCA group. To our knowledge, this is the first investigation to link changes in multiple acylcarnitine groups with cognition. Mapstone et al. (36) reported a downregulation or depletion of acylcarnitines C3 and C16:1-OH in older adults who were originally cognitively normal and then converted to mild cognitive impairment or AD over a 2-3-year follow-up. Ciavardelli et al. (17) reported lower plasma concentrations of several medium-chain acylcarnitines and in acetylcarnitine (C2) in AD patients compared to older adults with mild cognitive impairment or normal controls. Our findings are contrary to those of Mapstone and Ciavardelli with respect to the direction of the association, in that we observed elevated concentrations of short, medium, and long-chain acylcarnitines with a lower MoCA. Similarly, other chronic disease or dysfunctional states, such as cardiovascular disease and reduced physical function, are associated with elevated concentrations of circulating acylcarnitines (37, 38) . It is plausible that because we did not have participants with overt AD or dementia, we observed a phenomenon of accumulating circulating acylcarnitines that occurs in the early stages of cognitive decline and mitochondrial dysfunction, and a "tipping point" may occur where both the brain and mitochondrial function is so impaired that the fatty acid oxidation cascade is permanently shunted and decreasing concentrations of acylcarnitines are then observed. Permanent mitochondrial dysfunction has in fact been observed in brain tissue with severe traumatic brain injury (39) . We would need studies that longitudinally examine circulating biomarkers and cognition before, during, and after the transition from normal to impaired cognition to confirm or refute this hypothesis. Linking brain mitochondrial activity via positron emission tomography in conjunction with peripheral biomarker studies would provide further evidence for this model of substrate energy shifts associated with dementia (40) . Although previous studies have identified b-HBA as a potential direct marker of impaired cognitive function (17), this was not apparent in our study. The variability of b-HBA in this sample was an issue for detection of significant associations with cognition; however, the Spearman correlation (Rho = −0.18; p = .07) between visit 2 b-HBA and MoCA did show a trend for an association. Larger sample sizes likely could detect this link. Similar to our acylcarnitine findings, the direction of the relationship between b-HBA and MoCA would be in contrast to the findings of Ciavardelli and colleagues (17) . This could be in parallel with the accumulation or "log-jamming" of concentrations phenomenon we theorized with acylcarnitines in the subclinical stages of AD or dementia. The overt stages of disease would then see depletion of these concentrations as alternate fuel sources are utilized for energy. We did observe moderate to strong correlations (rho = 0.55-0.68) between b-HBA and short-chain acylcarnitines at both visits and their change between visits. This adds some support to this theory. Additionally, given the cost of a b-HBA assay (~$10.00) versus acylcarnitines using metabolomic profiling methods (~$75.00) further work is warranted to determine if b-HBA could be used as a proxy biomarker measure of accumulating acylcarnitines, particularly short-chain species given their consistent associations with cognitive status in this study.
The role of amino acids in cognitive function is complex. Of the 15 amino acids measured in the study subjects, a significant association with lower cognitive test scores was seen with glutamate/ glutamic acid, ornithine, and proline only. One theory posits that amino acids may serve as fuel in the brain in a compensatory role in the absence of sufficient glucose for metabolism (26) , which may be secondary to the mitochondria's inability to catabolize glucose. Given the abundance of glutamate/glutamic acid in the nervous system, it is logical, within the construct of this theoretical model, that this amino acid would fill a compensatory role in the brain. Previous studies have also found altered levels of glutamine in AD (41) and in schizophrenia (42) .
Mapstone and colleagues reported lower plasma concentrations of proline in a group of normal cognitive functioning community dwelling older adults who later converted to AD or mild cognitive impairment compared to a normal matched group. Our findings of higher proline concentrations being associated with lower MoCA are in contrast; however, as our cohort ages we will be able to better compare these findings with respect to conversion to dementia or not. It has also been reported that proline may disrupt the glutamate-glutamine cycle in the brain, which is critical in normal neuronal activity (24) . Interestingly, we also found stronger associations in the >26 MoCA group between glutamate/glutamic acid and proline at visits 1 (rho = 0.43) and 2 (rho = 0.49), and in their change between visits (rho = 0.37), compared to the <26 MoCA group (visit 1 rho = 0.35, visit 2 rho = 0.35, and change rho = 0.02). As this work moves forward we will be interested in further exploring if this represents a homeostatic disruption between glutamate/ glutamic acid and proline with timing of dementia onset. Our findings of an association between ornithine and MoCA, is novel, and may be due to the lack of studies published to date, or it may be an aberrant finding. As a group, given that amino acids are acquired primarily from diet, the continued examination of the role amino acids in cognitive function, coupled with findings from research focused on the gut-brain interaction, could lead to new dietary or pharmaceutical therapies (43). 
Study Limitations
The main limitation of this study is the availability of only one cognitive assessment tool to reflect cognitive performance at one point in time. Although the MoCA is a standardized and validated tool, a diagnosis of cognitive impairment relies on a detailed patient history, thorough physical and neurologic examinations, and laboratory and imaging studies. Additionally, while regression models were adjusted for covariates such as chronic conditions, age, grip strength, and mental functioning, information about medications was not available for analysis. However, the study cohort is a relatively healthy group of individuals and unlikely to be exposed to significant polypharmacy. We were also unable to determine temporality of change in covariates (ie, health conditions, grip strength, mental functioning, etc.) in relation to biomarkers and cognition. This work is planned and is important in determining the sequence of these changes and their impact on cognition. We also recognize that with this sample size dichotomizing MoCA scores resulted in loss of statistical power to observe significant association or resulted in imprecision and wide confidence intervals. However, we believe the dichotomized groups' clinical relevance outweigh the loss of statistical power. Due to the exploratory nature of this study, we did not correct for multiple comparisons. Thus type I error should be considered when interpreting our findings. Finally, due to the self-reporting of medical diagnoses rather than review of medical records, there is potential for recall bias.
Future Work
This study is the first step in a larger research agenda in which we intend to examine relationships among joint patterns of change in biomarkers and cognitive functioning throughout midlife and older adulthood using long-term serial data. This study has allowed us to narrow our exploratory examination of a large volume of biomarkers to a more focused and honed group of biomarkers (eg, short-chain acylcarnitines, proline, b-HBA). These more targeted observational studies will then be tested for replication in larger, well-characterized samples, and in clinical populations including patients with and without cognitive decline and overt dementia. Furthermore, we intend to examine the role of inflammatory, coagulation, and endothelial function, and other biomarkers on cognition.
Supplementary Material
Supplementary data is available at The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences online.
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